Showing results (1671-1680 of 1,880) with videos related to
Sort By:
Pageof 188
Immunotherapy|June 29, 2021
Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?Khalil El Gharib, Eddy Lilly, Roy ChebelImmunotherapy|June 30, 2021
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumabAntonello Veccia, Vincenzo Sforza, Emanuela Vattemi, et al.Immunotherapy|June 30, 2021
Immunotherapy for cholangiocarcinoma: a 2021 updateNikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, et al.Immunotherapy|June 3, 2021
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysisEkaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, et al.Immunotherapy|April 7, 2020
Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejectionAbhishek Pandey, Deirdre J CohenImmunotherapy|January 7, 2020
Safety evaluation of a multiallergen immunotherapy treatment in polyallergic patients. APOLO observational studyPilar Alba, Victoria Moreno, José Arias-Irigoyen, et al.Immunotherapy|April 3, 2020
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerationsErik Anderson, Richard FurieImmunotherapy|September 28, 2020
Immunotherapy in advanced non-small-cell lung cancer with EGFR mutationsFangfang Liu, Xun Yuan, Jizong Jiang, et al.Immunotherapy|September 16, 2020
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapyMelissa Bersanelli, Teresa Zielli, Fabiana Perrone, et al.Immunotherapy|September 29, 2020
Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancerAlexander Philipovskiy, Karinn Chambers, Ioannis Konstantinidis, et al.Pageof 188